117 related articles for article (PubMed ID: 29494610)
1. Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer.
Hou S; Dai J
PLoS One; 2018; 13(3):e0192812. PubMed ID: 29494610
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
[TBL] [Abstract][Full Text] [Related]
3. Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma.
Liu G; Chen L; Ren H; Liu F; Dong C; Wu A; Liu Z; Zheng Y; Cheng X; Liu L
Int J Biol Sci; 2018; 14(14):2012-2022. PubMed ID: 30585265
[No Abstract] [Full Text] [Related]
4. High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer.
Shen Y; Lin H; Chen K; Ge W; Xia D; Wu Y; Lu W
J Ovarian Res; 2022 Apr; 15(1):48. PubMed ID: 35477477
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
6. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
7. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
9. Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell lines.
Bonfrer JM; Linders TC; Hageman PC; Hilkens JG; Korse CM; Molthoff CF
Tumour Biol; 1997; 18(4):232-40. PubMed ID: 9218008
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
Hata K; Osaki M; Dhar DK; Nakayama K; Fujiwaki R; Ito H; Nagasue N; Miyazaki K
Cancer Chemother Pharmacol; 2004 Jan; 53(1):68-74. PubMed ID: 14569416
[TBL] [Abstract][Full Text] [Related]
11. Prediction of chemo-response in serous ovarian cancer.
Gonzalez Bosquet J; Newtson AM; Chung RK; Thiel KW; Ginader T; Goodheart MJ; Leslie KK; Smith BJ
Mol Cancer; 2016 Oct; 15(1):66. PubMed ID: 27756408
[TBL] [Abstract][Full Text] [Related]
12. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
13. [Expression of COP9, JAK2, HSP and NADH in ovarian carcinoma tissues after taxol-chemotherapy and their significance].
Li HX
Zhonghua Fu Chan Ke Za Zhi; 2008 Jul; 43(7):528-32. PubMed ID: 19080518
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
Tang L; Zheng M; Xiong Y; Ding H; Liu FY
Ai Zheng; 2008 Sep; 27(9):951-5. PubMed ID: 18799034
[TBL] [Abstract][Full Text] [Related]
15. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
16. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
17. Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2020 Jul; 177():113965. PubMed ID: 32278794
[TBL] [Abstract][Full Text] [Related]
18. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
20. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
